Scientists have shown new genetic evidence that could strengthen the link between the role of dietary fats and colon cancer progression.
The study, led by Arizona State University researcher and physician Raymond DuBois, has identified a molecular culprit, called peroxisome proliferator-activated receptor delta (PPAR delta), which, when deleted in a mouse model of colon cancer, stopped key steps required for the initiation and progression of tumor growth.
"This study has shown without a doubt there is a new function for a key molecule, PPAR delta, in the initiation and progression of colon cancer," said DuBois, executive director of ASU's Biodesign Institute. "These results also provide a new rationale for developing therapeutics that could block PPAR delta to treat inflammatory bowel disease and colorectal cancer."
Read the complete press release here: http://bit.ly/1f26xVu
Source: Arizona State University News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More